138 related articles for article (PubMed ID: 37995570)
1. The role of BATF2 deficiency in immune microenvironment rearrangement in cervical cancer - New biomarker benefiting from combination of radiotherapy and immunotherapy.
Zong Y; Chang Y; Huang K; Liu J; Zhao Y
Int Immunopharmacol; 2024 Jan; 126():111199. PubMed ID: 37995570
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of
Kanemaru H; Yamane F; Fukushima K; Matsuki T; Kawasaki T; Ebina I; Kuniyoshi K; Tanaka H; Maruyama K; Maeda K; Satoh T; Akira S
Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7331-E7340. PubMed ID: 28808017
[TBL] [Abstract][Full Text] [Related]
3. BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs.
Liu Z; Wei P; Yang Y; Cui W; Cao B; Tan C; Yu B; Bi R; Xia K; Chen W; Wang Y; Zhang Y; Du X; Zhou X
Clin Cancer Res; 2015 Apr; 21(7):1752-63. PubMed ID: 25762344
[TBL] [Abstract][Full Text] [Related]
4. BATF2 inhibits PD-L1 expression and regulates CD8+ T-cell infiltration in non-small cell lung cancer.
Liu J; Li J; Tuo Z; Hu W; Liu J
J Biol Chem; 2023 Nov; 299(11):105302. PubMed ID: 37777155
[TBL] [Abstract][Full Text] [Related]
5. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance.
Li T; Zhang W; Niu M; Wu Y; Deng X; Zhou J
Front Immunol; 2024; 15():1342647. PubMed ID: 38550593
[TBL] [Abstract][Full Text] [Related]
6. Targeting Batf2 for infectious diseases and cancer.
Guler R; Roy S; Suzuki H; Brombacher F
Oncotarget; 2015 Sep; 6(29):26575-82. PubMed ID: 26376615
[TBL] [Abstract][Full Text] [Related]
7. Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer.
Lin Y; Zhou X; Peng W; Wu J; Wu X; Chen Y; Cui Z
BMC Cancer; 2021 Sep; 21(1):1062. PubMed ID: 34565331
[TBL] [Abstract][Full Text] [Related]
8. BATF2 inhibits chemotherapy resistance by suppressing AP-1 in vincristine-resistant gastric cancer cells.
Yang W; Zhao S; Wu B; Xu J; Wu Z; Guo J; Zeng R
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1279-1288. PubMed ID: 31549215
[TBL] [Abstract][Full Text] [Related]
9. m
Xie JW; Huang XB; Chen QY; Ma YB; Zhao YJ; Liu LC; Wang JB; Lin JX; Lu J; Cao LL; Lin M; Tu RH; Zheng CH; Huang CM; Li P
Mol Cancer; 2020 Jul; 19(1):114. PubMed ID: 32650804
[TBL] [Abstract][Full Text] [Related]
10. BATF2 balances the T cell-mediated immune response of CADM with an anti-MDA5 autoantibody.
Li C; Liu M; Liu K; Li M; Liu Y; Li T; Wei Y; Long Y; He W; Shi X; Li Y; Zhang H
Biochem Biophys Res Commun; 2021 Apr; 551():155-160. PubMed ID: 33740622
[TBL] [Abstract][Full Text] [Related]
11. Decreased expression of BATF2 is significantly associated with poor prognosis in oral tongue squamous cell carcinoma.
Wen H; Chen Y; Hu Z; Mo Q; Tang J; Sun C
Oncol Rep; 2014 Jan; 31(1):169-74. PubMed ID: 24252932
[TBL] [Abstract][Full Text] [Related]
12. CD36-BATF2\MYB Axis Predicts Anti-PD-1 Immunotherapy Response in Gastric Cancer.
Jiang Q; Chen Z; Meng F; Zhang H; Chen H; Xue J; Shen X; Liu T; Dong L; Zhang S; Xue R
Int J Biol Sci; 2023; 19(14):4476-4492. PubMed ID: 37781029
[TBL] [Abstract][Full Text] [Related]
13. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
Liang Y; Wang W; Zhu X; Yu M; Zhou C
Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
[TBL] [Abstract][Full Text] [Related]
15. Effect of immunotherapy on the immune microenvironment in advanced recurrent cervical cancer.
Chen R; Yang W; Li Y; Cheng X; Nie Y; Liu D; Wang H
Int Immunopharmacol; 2022 May; 106():108630. PubMed ID: 35189471
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma.
Ma H; Liang X; Chen Y; Pan K; Sun J; Wang H; Wang Q; Li Y; Zhao J; Li J; Chen M; Xia J
Int J Cancer; 2011 Feb; 128(4):771-7. PubMed ID: 20473897
[TBL] [Abstract][Full Text] [Related]
17. BATF2 prevents T-cell-mediated intestinal inflammation through regulation of the IL-23/IL-17 pathway.
Kayama H; Tani H; Kitada S; Opasawatchai A; Okumura R; Motooka D; Nakamura S; Takeda K
Int Immunol; 2019 May; 31(6):371-383. PubMed ID: 30753547
[TBL] [Abstract][Full Text] [Related]
18. Batf2/Irf1 induces inflammatory responses in classically activated macrophages, lipopolysaccharides, and mycobacterial infection.
Roy S; Guler R; Parihar SP; Schmeier S; Kaczkowski B; Nishimura H; Shin JW; Negishi Y; Ozturk M; Hurdayal R; Kubosaki A; Kimura Y; de Hoon MJ; Hayashizaki Y; Brombacher F; Suzuki H
J Immunol; 2015 Jun; 194(12):6035-44. PubMed ID: 25957166
[TBL] [Abstract][Full Text] [Related]
19. Influence of chemoradiation on the immune microenvironment of cervical cancer patients.
Herter JM; Kiljan M; Kunze S; Reinscheid M; Ibruli O; Cai J; Niu L; Heßelmann I; Trommer M; Herter-Sprie GS; Köhler C; Marnitz S
Strahlenther Onkol; 2023 Feb; 199(2):121-130. PubMed ID: 36251031
[TBL] [Abstract][Full Text] [Related]
20. The tumor-suppressive role of BATF2 in esophageal squamous cell carcinoma.
Han T; Wang Z; Yang Y; Shu T; Li W; Liu D; Li P; Qi R; Ren Y; Li L; Liu H; Zhang S; Zhang L
Oncol Rep; 2015 Sep; 34(3):1353-60. PubMed ID: 26135942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
